कृपया अन्य खोज का प्रयास करें
Cereno Scientific AB (publ), clinical stage biotechnology company, develops therapeutics to treat cardiovascular and rare diseases worldwide. The company’s lead drug candidate is CS1, a product candidate that is in phase II clinical trial for the treatment of rare disease pulmonary arterial hypertension, as well as a histone deacetylase (HDAC) inhibitor that acts as an epigenetic modulator with pressure-reducing, reverse-remodeling, anti-inflammatory, anti-fibrotic, and antithrombotic properties. Its preclinical drug candidates comprise CS585 and CS014 that is in pre clinical stage for the treatment of cardiovascular diseases. The company has a collaboration agreement with the University of Michigan for the preclinical development program of CS585 and CS014, are preclinical drug candidate for cardiovascular diseases; and Abbott for use of CardioMEMS HF System. Cereno Scientific AB (publ) was founded in 2012 and is headquartered in Gothenburg, Sweden.
नाम | आयु | पहले | शीर्षक |
---|---|---|---|
Joakim Soderstrom | 40 | 2023 | Chairperson |
Sten R. Sorensen | 65 | 2015 | CEO & Director |
Gunnar Olsson | - | 2018 | Director & Member of Scientific Advisory Board |
Anders Svensson | 73 | 2018 | Director |
Faiez Zannad | - | - | Member of Scientific Advisory Board |
Raymond L. Benza | - | 2021 | Member of Scientific Advisory Board |
Gordon H. Williams | - | - | Member of Scientific Advisory Board |
Deepak L. Bhatt | 56 | - | Member of Scientific Advisory Board |
Jeppe Ovli Ovlesen | 62 | 2023 | Director |
Bertram Pitt | 92 | - | Chairman of Scientific Advisory Board |
क्या आप सच में %USER_NAME% को ब्लॉक करना चाहते हैं?
ऐसा करके, आप और %USER_NAME% नहीं देख पाएंगे किसी अन्य के Investing.com की पोस्ट में से कोई भी।
%USER_NAME% को सफलतापूर्वक आपकी ब्लॉक सूची में जोड़ लिया गया है
क्योंकि आपने इस व्यक्ति को अनब्लॉक कर दिया है, आपको ब्लॉक को रिन्यू करने से पहले 48 घंटे प्रतीक्षा करनी होगी।
मुझे लगता है कि यह टिपण्णी:
धन्यवाद!
आपकी रिपोर्ट समीक्षा के लिए हमारे मॉडरेटर को भेजी गई है